Stoke Therapeutics, Inc.
NASDAQ:STOK
20.68 (USD) • At close September 5, 2025
Overzicht | Financiële gegevens
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Omzet
| 36.555 | 8.78 | 12.405 | 0 | 0 | 0 | 0 | 0 |
| Kosten van de omzet
| 0 | 4.729 | 3.535 | 2.23 | 1.926 | 0.45 | 0.214 | 0.113 |
| Brutowinst
| 36.555 | 8.78 | 12.405 | -2.23 | -1.926 | -0.45 | -0.214 | -0.113 |
| Brutowinstmarge
| 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Onderzoek- en ontwikkelingskosten
| 89.133 | 82.231 | 77.837 | 54.168 | 32.197 | 23.764 | 8.371 | 3.598 |
| Algemene en administratieve kosten
| 48.794 | 41.322 | 38.924 | 31.897 | 20.847 | 11.914 | 4.41 | 1.956 |
| Verkoop- en marketingkosten
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Verkoop-, algemene en administratieve kosten
| 48.794 | 41.322 | 38.924 | 31.897 | 20.847 | 11.914 | 4.41 | 1.956 |
| Overige kosten
| 0 | 0 | 0 | -2.23 | -1.926 | 0 | -0.01 | -0.004 |
| Bedrijfskosten
| 137.927 | 123.553 | 116.761 | 83.835 | 51.118 | 35.678 | 12.781 | 5.554 |
| Bedrijfsresultaat
| -101.372 | -114.773 | -104.356 | -86.065 | -53.044 | -35.678 | -12.781 | -5.554 |
| Bedrijfsresultaat ratio
| -2.773 | -13.072 | -8.412 | 0 | 0 | 0 | 0 | 0 |
| Totaal overige inkomsten en kosten netto
| 12.391 | 10.074 | 3.289 | 0.26 | 0.801 | 3.353 | 0.26 | -0.004 |
| Inkomen voor belasting
| -88.981 | -104.699 | -101.067 | -85.805 | -52.243 | -32.325 | -12.521 | -5.558 |
| Inkomen voor belasting ratio
| -2.434 | -11.925 | -8.147 | 0 | 0 | 0 | 0 | 0 |
| Belastingkosten
| 0 | 0 | -7.957 | -1.094 | 0 | -3.801 | 0 | 0 |
| Nettowinst
| -88.981 | -104.699 | -101.067 | -85.805 | -52.243 | -32.325 | -12.521 | -5.558 |
| Nettowinstmarge
| -2.434 | -11.925 | -8.147 | 0 | 0 | 0 | 0 | 0 |
| WPA (Winst Per Aandeel)
| -1.65 | -2.38 | -2.6 | -2.34 | -1.56 | -1.59 | -0.53 | -0.24 |
| Verwaterde WPA
| -1.65 | -2.38 | -2.6 | -2.34 | -1.56 | -1.59 | -0.53 | -0.24 |
| EBITDA
| -99.195 | -112.304 | -102.81 | -83.575 | -50.317 | -35.228 | -12.567 | -5.441 |
| EBITDA ratio
| -2.714 | -12.791 | -8.288 | 0 | 0 | 0 | 0 | 0 |